GlassScriptPhysician profile
Cortney Lynn Langerholc
NPI 1386260396
$5,591.14
in general payments reported to CMS, 2019-2025
42 companies · $925 in 2025
The $925 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $600 · 2022: $1,103 · 2023: $1,510 · 2024: $1,452 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,822 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,821.76 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,148.26 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $535.39 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $484.93 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $377.83 | 2022-2025 | |
| Novo Nordisk INC | $362.64 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $329.90 | 2021-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $211.86 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $195.28 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $194.04 | 2021-2025 | Freestyle Libre 3, Eterna, Infinity |
| E.R. Squibb & Sons, L.L.C. | $187.30 | 2021-2024 | Eliquis, Camzyos |
| Astellas Pharma US INC | $179.78 | 2022-2024 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $127.19 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.20 | 2022-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $106.03 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $99.49 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $88.51 | 2021-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Exact Sciences Corporation | $87.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $80.54 | 2021-2025 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $75.73 | 2023-2024 | Rexulti |
| Boston Scientific Corporation | $50.17 | 2022 | |
| Novartis Pharmaceuticals Corporation | $48.93 | 2021-2025 | |
| Electromed, INC. | $46.95 | 2021 | |
| Aimmune Therapeutics, INC. | $40.76 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $38.50 | 2021 | |
| Neurelis, INC. | $34.81 | 2023 | Valtoco |
| Xeris Pharmaceuticals, INC. | $33.69 | 2022 | |
| Stryker Corporation | $29.84 | 2025 | Clottriever Bold Catheter |
| Sanofi-Aventis U.S. LLC | $29.21 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $27.41 | 2023-2024 | Xarelto |
| Ucb, INC. | $23.66 | 2022 | |
| Axsome Therapeutics, INC. | $21.72 | 2025 | Auvelity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.57 | 2024 | Lifevest |
| Supernus Pharmaceuticals, INC. | $20.22 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $17.17 | 2023 | Glassia |
| Tactile Systems Technology INC | $15.90 | 2025 | Flexitouch Plus, Nimbl |
| Smith+Nephew, INC. | $15.85 | 2023 | Grafix Pl |
| Bioxcel Therapeutics, INC. | $15.74 | 2023 | Igalmi |
| Indivior INC. | $15.25 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.63 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $13.97 | 2023 | Gemtesa |
| Sanofi Pasteur INC. | $13.94 | 2021 | |
| Neurocrine Biosciences, INC. | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cortney Langerholc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.